Urovant Sciences (UROV) Reports Q2 Loss of $1.23

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. ANT
4. CDNS
5. META
6. BA
7. SPY
8. HOOD
9. INTC
10. JBLU

Go back to Urovant Sciences (UROV) Reports Q2 Loss of $1.23

Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update

November 12, 2018 4:05 PM EST

BASEL, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial results for the three and six months ended September 30, 2018 and announced corporate updates.

Recent Business Highlights

Completed enrollment in international Phase 3 trial for vibegron in adults with symptoms of overactive bladder (OAB) as defined by urge urinary incontinence, urgency, and urinary frequency Positive results from the international Phase 2b study for vibegron in adults with OAB recently published in... More